Platelet Transfusion in Dengue Fever
Platelet transfusion is NOT recommended for patients with dengue fever and thrombocytopenia in the absence of major bleeding. 1
Key Recommendation
The 2025 AABB/ICTMG international guidelines provide a strong recommendation against routine platelet transfusion in consumptive thrombocytopenia due to dengue without major bleeding. 1 This represents the most current, high-quality guidance and supersedes older general transfusion thresholds.
Evidence Supporting This Approach
Lack of Efficacy in Dengue
Prophylactic platelet transfusion does not prevent bleeding in dengue patients, even with severe thrombocytopenia (platelet count <20 × 10³/μL). 2 A study of 256 dengue patients with severe thrombocytopenia found that bleeding rates, platelet recovery, and clinical outcomes were identical whether patients received transfusion or not. 2
Approximately 50% of dengue patients fail to respond to platelet transfusion (defined as inadequate post-transfusion platelet increment), and even responders show no clinical benefit in preventing severe bleeding or shortening time to cessation of bleeding. 3
Meta-analyses demonstrate no mortality or bleeding benefit from liberal versus restrictive platelet transfusion strategies in dengue. 4
Significant Risks
Platelet transfusion in dengue carries substantial risks including severe transfusion reactions and mortality. 3 One randomized trial reported three severe transfusion reactions and two deaths in the treatment group receiving platelets. 3
General transfusion risks include allergic reactions, febrile reactions, and bacterial sepsis (the most common infectious complication from any blood product). 5
When Platelet Transfusion IS Indicated in Dengue
Platelet transfusion should be considered ONLY in the following specific situations:
Active major bleeding (severe gastrointestinal hemorrhage, intracranial hemorrhage, or life-threatening bleeding from any site) 6
Invasive procedures requiring hemostasis (emergency surgery, invasive intensive care procedures) with target platelet count >50 × 10³/μL 6
Possibly for platelet counts <5 × 10³/μL with associated risk factors (though evidence is weak) 6
Dosing When Transfusion Is Required
Transfuse up to a single apheresis unit or equivalent (approximately 3-4 × 10¹¹ platelets). 5, 6
Greater doses are not more effective than a single apheresis unit. 5
Target platelet count >50 × 10³/μL for major surgery or invasive procedures. 5, 6
Clinical Pitfalls to Avoid
Do not transfuse based solely on platelet count thresholds. The standard threshold of 10 × 10³/μL for hypoproliferative thrombocytopenia does NOT apply to dengue's consumptive thrombocytopenia. 1
Inappropriate transfusion occurs frequently - one audit found 36.6% of platelet transfusions in dengue were inappropriate, given to patients with counts >20 × 10³/μL without bleeding. 7
Platelet counts typically recover spontaneously during the second week after fever onset without intervention. 6
Lower baseline platelet counts predict transfusion failure - patients are more likely to be non-responders if starting counts are very low. 3
Restrictive Strategy Validation
A restrictive transfusion strategy in dengue has been proven feasible and safe. 6 In a prospective study of 350 dengue patients, only 9 (2.6%) required platelet transfusion using strict criteria, and all patients except three who died from other causes recovered without complications. 6